NCT00359905View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

PHASE3CompletedINTERVENTIONAL
Enrollment

1,228

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

January 31, 2008

Conditions
Benign Prostatic Hyperplasia
Interventions
DRUG

Silodosin

8 mg daily for 12 weeks

DRUG

Tamsulosin

0.4 mg daily for 12 weeks

DRUG

Placebo

once daily for 12 weeks

Trial Locations (1)

S10 2JF

Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield

All Listed Sponsors
lead

RECORDATI GROUP

INDUSTRY

NCT00359905 - Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH | Biotech Hunter | Biotech Hunter